UNSPSC 51111840: Cetrorelix

This classification denotes a gonadotropin releasing hormone inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OON1HFZ4BA. European Medicines Agency schedules Cetrorelix in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07459MIG. Cetrorelix generally arises in the molecular formula C70H92CLN17O14.

The term CETRORELIX is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, no. 3 1991, list 31.) CETRORELIX is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cetrorelix under HS 29371900 and SITC 54154. As of Q4 2014, CETRORELIX remains the US FDA Preferred Term for this commodity. Cetrorelix bears US NLM identifiers UMLS ID C0209366 and NCI Concept Code C2481.

UNSPSC 51111840 Cetrorelix is a Commodity code for a specific pharmaceutical active ingredient used primarily in fertility and reproductive health treatments. State and local governments procure cetrorelix and other generic multi-source pharmaceuticals through cooperative purchasing vehicles and health system contracts, typically as part of broader pharmaceutical supply agreements negotiated with manufacturers and distributed through authorized wholesalers. The issuing bodies include state health departments, state purchasing offices administering multistate cooperatives, county health systems, and municipal hospitals and clinics that stock formularies for patient care.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. The procurement requires manufacturers to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with comprehensive pricing for identified pharmaceutical products using specific National Drug Codes. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place, and carry commercial general liability insurance of $5,000,000 per occurrence. The contract term runs two years for new responders with optional extensions through June 30, 2028, and evaluation emphasizes price competitiveness (75 percent weight) alongside fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. No set-aside designations or dollar range is disclosed in available documentation.